http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2331424-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b1632a659e6671b8c2f30937a1cdf92 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-14 |
| filingDate | 2002-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_415eb554d65a42c3b1e3add8e6a4d701 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8ca898cc471b619d9c5c151ad23022b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b4a56f7749d5e6958c9cb924c005bb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a2989e489a4fd285e1009f1352fb362 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d74218c9e5d5fe015f3f67f947687294 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d2480b07164effd3004741ac2a110f8 |
| publicationDate | 2008-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2331424-C2 |
| titleOfInvention | Topical formulation, containing spironolactone nanoparticles |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to topical formulation with: spironolactone nanoparticles, containing medium-diameter nanoparticles measured by photonic correlation spectroscopy technique, in the range approximately 300 nm to 900 nm, and dispersion of solid polar lipids crystals in polar liquid, with additional stabiliser. The nanoparticles are included in crystal structure formed by solid polar lipids crystals; the lipids mentioned being directed their hydrophilic ends outside, and hydrophobic ends inside, relative to spironolactone nanoparticles. Items of the patent application are also as follows: method of producing the formulation, the crystal lattice arrangement of solid polar lipids crystals with spironolactone nanoparticles included, and use of the nanosuspension with structure mentioned for medication producing, intended for therapy in anti-androgen responding conditions. n EFFECT: achieving of high stability formulation and increased bioavailability of spironolactone. n 17 cl, 4 ex, 8 tbl, 11 dwg |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10166231-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11389448-B2 |
| priorityDate | 2002-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.